{
    "id": "aba52bdc-99f1-4e08-a0c6-f7ec5176a178",
    "indications": "VYLOY, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)‑negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive as determined by an FDA-approved test [see Dosage and Administration (2.1) and Clinical Studies (14)].",
    "contraindications": "• Administer by intravenous infusion only . Do not administer VYLOY as an intravenous push or bolus. ( 2.6 ) • The recommended first dose of VYLOY is 800 mg/m 2 followed by 600 mg/m 2 every 3 weeks or 400 mg/m 2 every 2 weeks. ( 2.3 )",
    "adverseReactions": "None.",
    "ingredients": [
        {
            "name": "ZOLBETUXIMAB",
            "code": "TF5MPQ8WGY"
        },
        {
            "name": "ARGININE",
            "code": "94ZLA3W45F"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "PHOSPHORIC ACID",
            "code": "E4GA8884NN"
        }
    ],
    "organization": "Astellas Pharma US, Inc.",
    "name": "VYLOY",
    "effectiveTime": "20250324"
}